Contact information
Research groups
David Kerr
CBE FMedSci FRCP
Professor of Cancer Medicine
- Consultant Physician
Genetics and Genomics
In collaboration with Dr Rachel Midgley, Oncology Clinical Trials Office, we have conducted a series of international adjuvant trials of chemotherapy for colorectal cancer. In parallel, we have established a biorepository of tissue and constitutional DNA (n=3500) which has allowed us to collaborate with Ian Tomlinson to generate a number of cancer susceptibility SNPs and commercial partners to characterise a prognostic mRNA signature which assists in selection of patients for chemotherapy. We are currently developing biomarkers for the anti-angiogenic agent bevacizumab.
Key publications
-
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article
Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557
Recent publications
-
Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?
Journal article
Kenseth A. et al, (2024), Pharmacoeconomics, 42, 679 - 691
-
Unification of Efforts to Improve Global Access to Cancer Therapeutics: Report From the 2022/2023 Access to Essential Cancer Medicines Stakeholder Summit.
Journal article
Briercheck E. et al, (2024), JCO Glob Oncol, 10
-
Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes.
Journal article
Chen Z. et al, (2024), Nat Commun, 15
-
An Explainable Coarse-to-Fine Survival Analysis Method on Multi-Center Whole Slide Images
Journal article
Wang H. et al, (2024), IEEE Transactions on Artificial Intelligence, 5, 1316 - 1327
-
Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.
Journal article
Frei AL. et al, (2024), Lancet Oncol, 25, 198 - 211